Large Cap BSE: 500124 NSE: DRREDDY
-12.8 (-0.29%)
As on 02 December, 2022 | 01:06

Dr. Reddy's Laboratories Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume


Start SIP

Dr. Reddy's Laboratories Share Price

Dr. Reddy's Laboratories Share Returns

  • Over 1 Month -1.34%
  • Over 3 Month 6.48%
  • Over 6 Month 3.6%
  • Over 1 Year -2.87%

Dr. Reddy's Laboratories Key Statistics

P/E Ratio 23.9
PEG Ratio 0.4
Market Cap Cr 74,498
Price to Book Ratio 3.9
EPS 97.8
Dividend 0.7
Relative Strength Index 54.91
Money Flow Index 64.74
MACD Signal 12.77
Average True Range 87.47

Dr. Reddy's Laboratories Investment Rating

  • Master Rating:
  • Dr. Reddy's Laboratories has an operating revenue of Rs. 22,377.90 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 14% is healthy, ROE of 11% is good. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 5% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It has recently broken out of a base in its weekly chart and is trading around 0% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 91 which is a GREAT score indicating consistency in earnings, a RS Rating of 49 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 124 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Dr. Reddy's Laboratories Financials
IndicatorSep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 4,8663,6163,6323,4803,8233,4343,351
Operating Expenses Qtr Cr 3,0783,0512,9892,8663,0752,8722,748
Operating Profit Qtr Cr 1,803580670614748562603
Depreciation Qtr Cr 226222205205207197211
Interest Qtr Cr 21013811717
Tax Qtr Cr 577252147123200131145
Net Profit Qtr Cr 1,116500420341449413312

Dr. Reddy's Laboratories Technicals


Current Price
-12.8 (-0.29%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 4435.23
  • 50 Day
  • 4392.91
  • 100 Day
  • 4338.06
  • 200 Day
  • 4257.61
  • 20 Day
  • 4454.99
  • 50 Day
  • 4382.54
  • 100 Day
  • 4326.41
  • 200 Day
  • 4255.96

Dr. Reddy's Laboratories Resistance and Support

First Resistance 4523.07
Second Resistance 4558.99
Third Resistance 4600.02
RSI 54.91
MFI 64.74
MACD Single Line 12.77
MACD 12.09
First Resistance 4446.12
Second Resistance 4405.09
Third Resistance 4369.17

Dr. Reddy's Laboratories Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 430,472 26,448,200 61.44
Week 470,418 28,827,215 61.28
1 Month 496,824 26,341,624 53.02
6 Month 461,632 21,881,336 47.4

Dr. Reddy's Laboratories Result Highlights

Dr. Reddy's Laboratories Synopsis


Dr. Reddy's Labs is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 14405.20 Cr. and Equity Capital is Rs. 83.20 Cr. for the Year ended 31/03/2022. Dr. Reddy's Laboratories Ltd. is a Public Limited Listed company incorporated on 24/02/1984 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L85195TG1984PLC004507 and registration number is 004507.
Market Cap 74,498
Sales 15,659
Shares in Float 12.15
No of funds 740
Yield 0.67
Book Value 4.06
U/D Vol ratio 1.1
LTDebt / Equity
Alpha -0.03
Beta 0.58

Dr. Reddy's Laboratories

Owner NameSep-22Jun-22Mar-22Dec-21
Promoters 26.71%26.71%26.72%
Mutual Funds 12.84%14.21%14.12%
Insurance Companies 11.53%10.72%10.23%
Foreign Portfolio Investors 26.26%25.87%25.16%
Financial Institutions/ Banks 0.02%0.12%
Individual Investors 8.06%8.22%8.37%
Others 14.6%14.25%15.28%

Dr. Reddy's Laboratories Management

Name Designation
Mr. K Satish Reddy Chairman
Mr. G V Prasad Co-Chairman & Manag. Director
Mr. Leo Puri Independent Director
Mr. Prasad R Menon Independent Director
Ms. Shikha Sharma Independent Director
Mr. Allan Oberman Independent Director
Dr. Bruce L A Carter Independent Director
Ms. Kalpana Morparia Independent Director
Mr. Sridar Iyengar Independent Director
Mr. Arun Madhavan Kumar Independent Director

Dr. Reddy's Laboratories Forecast

Price Estimates


Other Analyst Rating

Dr. Reddy's Laboratories Corporate Action

Date Purpose Remarks
2022-10-28 Quarterly Results
2022-07-28 Quarterly Results
2022-05-19 Audited Results & Final Dividend
2022-01-28 Quarterly Results
2021-10-29 Quarterly Results

Dr. Reddy's Laboratories MF Shareholding

Name Amount(cr)
SBI Nifty 50 ETF 151468
SBI S&P BSE Sensex ETF 83302
HDFC Balanced Advantage Fund Growth 49709
ICICI Prudential Balanced Advantage Fund Growth 44002
UTI Nifty 50 Exchange Traded Fund 39494

About Company

Dr. Reddy's Laboratories is a worldwide pharmaceutical corporation headquartered in Hyderabad, Telangana, India. Kallam Anji Reddy, who had worked at the mentor institute Indian Drugs and Pharmaceuticals Limited, started the company. A vast variety of pharmaceuticals are produced and sold by Dr. Reddy in India and other countries. They produce about 190 medications, and 60 active pharmaceutical ingredients (APIs) for the production of pharmaceuticals, diagnostic tools, critical care products, and biotechnology products, among other things.

Dr. Reddys Laboratories Ltd- Growth History and Empire Expansion

“It was a dream. It was not a plan on the drawing board, no. But it was a dream.”


With one medicine in a 60-tonne facility close to Hyderabad, Dr. Reddy's launched its business in the Active Pharmaceutical Ingredients (API) category in 1984. It sent its first shipment of Methyldopa medication to West Germany in 1986. It is one of the top three API providers worldwide. They also entered the international market this year with the introduction of the API Methyldopa. In 1987, they received their first USFDA approval for the API Ibuprofen. They have been manufacturing omeprazole, one of the most well-known products, since 1991. They entered Russia, which at the time was the biggest international market, in 1992. To direct research into new cancer and diabetes medicines, the Dr. Reddy's Research Foundation was founded in 1993.

To address the needs of children, teenagers, and women who are at risk in both the economic and social spheres,In 1996, Dr. Reddy's Foundation was founded. They began their biologics business in 1998 with the goal of providing inexpensive access to expensive pharmaceuticals to Indian patients.

As part of their continued global expansion, they bought BMS Laboratories Limited and Meridian Healthcare in the UK in 2002 and released a drug for advanced prostate cancer in India, becoming the first company to introduce Bicalutamide in India. The corporation established Dr. Reddy's Foundation for Health Education and a breast cancer helpline in Mumbai.

In the US, ibuprofen was first made accessible as a generic medication in 2003.

To treat autoimmune diseases and tumors, including non-lymphoma, Hodgkin's introduced the first monoclonal antibody biosimilar in history in 2007. In 2009, revenue in Russia and the CIS exceeded $150 million. In 2012, revenue exceeded USD 2 billion.

By 2016 the business entered the market for branded consumer health goods by purchasing six OTC brands from Ducere Pharma The company just announced its entry into Colombia with a variety of excellent, cost-effective medications for cancer patients.

By purchasing six over-the-counter (OTC) brands from Ducere Pharma in 2016, the company entered the market for branded consumer health products. The business announced its arrival in Colombia with a selection of top-notch, reasonably priced drugs for people with cancer.

In 2017 they expanded their commercial operations in Europe as they introduced the generics portfolio in France. The company's subsidiary Aurigene Discovery Technologies launched a particular initiative to create oral immuno-oncology drugs in 2018. A crucial generic medicine for the treatment of opioid addiction was successfully introduced in the US. 2019 saw the entry of Dr. Reddy's Nutrition into the Indian nutrition market with the launch of Celevida, a ground-breaking product. For the cosmetic and aesthetic area, GLOWRIA, a 40-person, all-female medical representation team, was created. To provide a wide variety of COVID-19 medicines to India as the coronavirus pandemic spread around the globe, they got into significant relationships with international innovation businesses. In the US, they introduced the first generic Otic suspension product. In addition to some anti-allergy brands from the Glenmark portfolio in Russia, Ukraine, Kazakhstan, and Uzbekistan, they bought specific business divisions of Wockhardt in India. They joined the Science Based Targets program as the first pharmaceutical business in India.

Corporate Social Responsibility Information

The Company may carry out the following CSR-related projects or programs:

  • Fighting against hunger, poverty, and malnutrition, encouraging preventative care, cleanliness, and the provision of safe drinking water.
  • Projects to improve livelihoods and promote education, including special education and employment-enhancing vocation skills, particularly among children, women, older people, and people with disabilities.
  • Maintaining the quality of soil, air, and water while ensuring environmental sustainability, ecological balance, animal welfare, protection of flora and fauna, and agroforestry.
  • Education to promote Olympic, paralympic, and rural sports that are recognized nationwide.
  • Contribution to the prime minister's national relief fund, the PM CARES Fund, or any other fund established by the central government for the socio-economic development, relief, and welfare of the scheduled caste, tribes, other underprivileged classes, minorities, and women
  • Contributions to public-funded universities in the field of technology, national laboratories, and autonomous bodies engaged in conducting research in the fields of atomic energy, science, and technology
  • Contributions to incubators or research and development projects in the fields of science, technology, engineering, and medicine, funded by the Central Government or State Government or Public Sector Undertaking or any agency of the Central Government or State Government
  • Contributions to publicly funded research universities, national laboratories, and autonomous organizations conducting research in the fields of atomic energy, science, technology, biotechnology, pharmaceuticals, electronics, and information, as well as defense, agricultural, scientific, and industrial research, engineering, and medicine and listed in Schedule VII of the Act and its implementing regulations
  • projects for rural development.
  • Construction in slum areas.
  • Any other activities or subjects listed in Schedule VII of the Companies Act, 2013 (the Act) and the rules made thereunder, as amended from time to time, and circulars/notifications issued by statutory authorities.
  • Disaster management, including relief, rehabilitation, and reconstruction activities.

Dr. Reddy's Laboratories FAQs

What is Share Price of Dr. Reddy's Laboratories ?

Dr. Reddy's Laboratories share price is ₹4474 As on 02 December, 2022 | 00:52

What is the Market Cap of Dr. Reddy's Laboratories ?

The Market Cap of Dr. Reddy's Laboratories is ₹74498 Cr As on 02 December, 2022 | 00:52

What is the P/E ratio of Dr. Reddy's Laboratories ?

The P/E ratio of Dr. Reddy's Laboratories is 23.9 As on 02 December, 2022 | 00:52

What is the PB ratio of Dr. Reddy's Laboratories ?

The PB ratio of Dr. Reddy's Laboratories is 3.9 As on 02 December, 2022 | 00:52

Q) How to buy Dr. Reddys Laboratories Ltd shares?

Ans - You can easily buy the shares of Dr. Reddys Laboratories Ltd, by registering at 5Paisa and by setting up a Demat Account in your name.

Q) What is the 52-week high and low price of shares of Dr Reddys Laboratories Ltd.

Ans – Dr Reddys Laboratories Ltd shares have a 52-week high of Rs 5,614.60 and a 52-week low of Rs 3,654.

Q) What is the Return of Equity on shares of Dr Reddys Laboratories Ltd for the past 1 year?

Ans – The Return on Equity on shares of Dr Reddys Laboratories Ltd is 11.8% for last year.

Q) What is the face value of a share of Dr Reddys Laboratories Ltd?

Ans – The face value of a share of Dr Reddys Laboratories Ltd. is INR 5 per share.

What is Dr Reddys Laboratories's stock price CAGR?

Dr Reddys Laboratories stock price CAGR for 10 Years stands at 12%, 5 Years at 8%, 3 Years at 20%, and 1 Year at -2%.

What is the ROE of Dr Reddys Laboratories?

The ROE of Dr Reddys Laboratories is 11%.

Is Dr Reddys Laboratories a good investment?

Dr Reddy's Laboratories has an operating revenue of Rs. 20,442.10 Cr. on a trailing 12-month basis. Annual revenue growth of 7% is good, Pre-tax margin of 15% is great. As per analysts rating in the last 6 months, the recommendation is to HOLD Dr Reddys Laboratories.

Who is the CEO of Dr Reddys Laboratories

Erez Israeli is the Chief Executive Officer (CEO) at Dr Reddy's Laboratories since 1 Aug 2019.

What is the Profit before tax of Dr. Reddys Laboratories Ltd stock?

Profit before tax of Dr. Reddys Laboratories Ltd stock for the quarter ended March 2022 is Rs 567 crores.